eDSP (EryDex)
Ataxia-Telangiectasia (A-T)
Key Facts
About Quince Therapeutics
Quince Therapeutics is a clinical-stage biotech focused on transforming proven therapeutics through its innovative Autologous Intracellular Drug Encapsulation (AIDE) platform, which leverages a patient's own red blood cells for targeted, safer drug delivery. The company's most advanced candidate, eDSP, recently reported topline results from a pivotal Phase 3 trial in Ataxia-Telangiectasia (A-T), which did not meet its primary or key secondary endpoints, prompting a strategic review. Quince's strategy hinges on leveraging the AIDE platform's potential to improve the therapeutic index of corticosteroids and other drugs across multiple chronic inflammatory and rare diseases, though its near-term future is contingent on the outcome of its exploration of strategic alternatives.
View full company profile